Faster Candida auris identification? Thermo Fisher Scientific unveils new agar
Thermo Fisher Scientific launches chromogenic media to detect Candida auris faster. Explore what this means for labs and AMR strategy.
Medical Devices & Diagnostics
Pharma & Biotech
New HSS data question bleeding risks of NSAIDs in anticoagulated hip replacement patients
New HSS data challenge assumptions on aspirin, NSAIDs, and cefazolin in joint replacement. See what this means for bleeding, pain, and infection risk.
Pharma & Biotech
Can Acadia overturn EMA’s negative opinion on trofinetide for Rett syndrome?
Acadia seeks EU re-examination after CHMP rejects trofinetide for Rett syndrome. Read the regulatory and clinical implications.
Pharma & Biotech
Ono Pharmaceutical strengthens early-stage pipeline with Congruence platform deal
Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.
Pharma & Biotech
Meiji Seika Pharma wins EU orphan drug status for morcamilast in palmoplantar pustulosis
EU orphan status for morcamilast in PPP reshapes Meiji Seika Pharma’s European strategy. See what it means for PDE4 competition and rare dermatology.
Pharma & Biotech
Can Bioxytran’s ProLectin-M accelerate viral clearance in mild COVID-19?
Bioxytran reports early antiviral signal for ProLectin-M. Discover what this means for COVID-19 treatment strategy and regulatory risk.
Pharma & Biotech
Takeda and Protagonist near FDA decision on novel PV therapy rusfertide
FDA grants Priority Review to rusfertide for polycythemia vera. Discover what this means for treatment standards and market dynamics.
Medical Devices & Diagnostics
LRS wins FDA clearance to test ThermoSuit cooling device in pivotal ischemic stroke trial
Life Recovery Systems (LRS), a medical device developer headquartered in Alexandria, Louisiana, has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration to advance its ThermoSuit System into a pivotal clinical trial enrolling ischemic stroke patients. The study, which will enroll up to 160 patients across as many as eight hospitals,
Pharma & Biotech
Merck strengthens its women’s oncology position with KEYNOTE-B96 overall survival results
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.
Pharma & Biotech
Can ctDNA-guided bladder preservation become viable after Signatera’s ASCO GU data?
New ASCO GU data shows how Signatera ctDNA may guide bladder preservation and adjuvant therapy decisions in muscle-invasive bladder cancer. Read the analysis.